Program
Rituximab
Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.
Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.
Drug pageRituximab: every studyMany companies study it; this page follows only the 124 they lead. All 1,284 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 781 open or running | phase 4since Jan 18, 2007 | Apr 1, 2003 | none ahead |
| SymBio Pharmaceuticalsits history only | 50 open or running | phase 3since Dec 10, 2017 | Nov 18, 2008 | none ahead |
| AbbVieits history only | 40 open or running | phase 3since Jun 9, 2014 | Apr 20, 2012 | none ahead |
| AstraZenecaits history only | 42 open or running | phase 4since Aug 23, 2023 | Apr 8, 2016 | Oct 31, 2028phase 2 · NCT05951959 |
| Biogenits history only | 40 open or running | phase 4since Aug 23, 2004 | Mar 31, 2003 | none ahead |
| Takedaits history only | 40 open or running | phase 3since Apr 7, 2006 | Jun 11, 2004 | none ahead |
| Biocad | 30 open or running | phase 3since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| Celltrionits history only | 30 open or running | phase 1since Feb 8, 2012 | Feb 8, 2012 | none ahead |
| Favrilleits history only | 30 open or running | phase 3since Aug 4, 2004 | Aug 4, 2004 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 3since Oct 13, 2017 | Dec 14, 2015 | none ahead |
| ImmunityBioits history only | 22 open or running | phase 1since Oct 19, 2022 | Oct 19, 2022 | Oct 2027phase 1 · NCT06334991 |
| Mabionits history only | 20 open or running | phase 3since Jun 9, 2015 | Jun 9, 2015 | none ahead |
| Merckits history only | 20 open or running | phase 1since May 18, 2011 | May 18, 2011 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Bayerits history only | 10 open or running | phase 2since Jul 8, 2004 | Jul 8, 2004 | none ahead |
| Mabscaleits history only | 11 open or running | phase 1since Dec 7, 2023 | Dec 7, 2023 | none ahead |
| Pharmatechits history only | 10 open or running | phase 2since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| Probiomed S.A. de C.V.its history only | 10 open or running | phase 3since Jan 8, 2011 | Jan 8, 2011 | none ahead |
| Sinocelltech Groupits history only | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
Also a collaborator on its studies: ICON Clinical Research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, Roche Pharma and Chiron.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Biocad only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 3, 2012First study: phase 3 study in Lymphoma, FollicularFirst studyNCT01701232 · 174 enrolled · Colombia, India, Russian Federation and more
- Dec 20, 2012Phase 3 study in Arthritis, RheumatoidNCT01759030 · 181 enrolled · Belarus, India, Russian Federation and more
- Apr 4, 2016Phase 3 study in Arthritis, RheumatoidNCT02744196 · 159 enrolled
- Jan 29, 2026Named rituximabINNProposed as its International Nonproprietary Name in WHO's List 134 · before, MK-8808
TargetBeta
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 3 Biocad leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02744196Arthritis, Rheumatoid | 3 | Completed | Feb 2017 | 159 |
| NCT01759030Arthritis, Rheumatoid · Belarus, India, Russian Federation and more | 3 | Completed | Jul 2015 | 181 |
| NCT01701232Lymphoma, Follicular · Colombia, India, Russian Federation and more | 3 | Completed | Jan 2017 | 174 |
How it is read
Names in the registry
- “Rituximab”, 104 entries
- “rituximab”, 34 entries
- “rituximab [MabThera/Rituxan]”, 23 entries
- “Rituximab SC”, 2 entries
- “MK-8808”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 34 studies
- Lymphoma, Non-Hodgkin, 33 studies
- Lymphoma, Large B-Cell, Diffuse, 23 studies
- Lymphoma, Follicular, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.